Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Ahdoot

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
Expert Review of Clinical Pharmacology|June 30, 2021
Immunotherapy of High Risk Non-Muscle Invasive Bladder CancerMichael Ahdoot, Dan Theodorescu
Ophthalmic Plastic and Reconstructive Surgery|October 20, 2005
Granular cell tumor of the orbit: magnetic resonance imaging characteristicsMichael Ahdoot, I Rand Rodgers
BJU International|March 18, 2026
Alternate-day administration of intravesical gemcitabine and docetaxel to improve clinic utilisationJohn R Heard, Michael Ahdoot
The New England Journal of Medicine|June 4, 2020
Biopsy for Prostate Cancer Diagnosis. ReplyMichael Ahdoot, Baris Turkbey, Peter Pinto
The Journal of Urology|September 13, 2022
Editorial CommentAurash Naser-Tavakolian, Michael Nazmifar, Michael Ahdoot
The Journal of Urology|February 8, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterPeris R Castaneda, Michael Ahdoot, Charles J Rosser
Expert Review of Molecular Diagnostics|November 13, 2024
Biomarkers of treatment response in bladder cancerJohn R Heard, Michael Ahdoot, Dan Theodorescu, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 17, 2009
Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cellsSeth P Epstein, Michael Ahdoot, Edward Marcus, et al.
Frontiers in Oncology|April 17, 2023
Identifying novel biomarkers associated with bladder cancer treatment outcomesPeris R Castaneda, Dan Theodorescu, Charles J Rosser, et al.
Prostate Cancer and Prostatic Diseases|March 5, 2022
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomesJohn R Heard, Aurash Naser-Tavakolian, Michael Nazmifar, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
Expert Review of Clinical Pharmacology|June 30, 2021
Immunotherapy of High Risk Non-Muscle Invasive Bladder CancerMichael Ahdoot, Dan Theodorescu
Ophthalmic Plastic and Reconstructive Surgery|October 20, 2005
Granular cell tumor of the orbit: magnetic resonance imaging characteristicsMichael Ahdoot, I Rand Rodgers
BJU International|March 18, 2026
Alternate-day administration of intravesical gemcitabine and docetaxel to improve clinic utilisationJohn R Heard, Michael Ahdoot
The New England Journal of Medicine|June 4, 2020
Biopsy for Prostate Cancer Diagnosis. ReplyMichael Ahdoot, Baris Turkbey, Peter Pinto
The Journal of Urology|September 13, 2022
Editorial CommentAurash Naser-Tavakolian, Michael Nazmifar, Michael Ahdoot
The Journal of Urology|February 8, 2023
Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. LetterPeris R Castaneda, Michael Ahdoot, Charles J Rosser
Expert Review of Molecular Diagnostics|November 13, 2024
Biomarkers of treatment response in bladder cancerJohn R Heard, Michael Ahdoot, Dan Theodorescu, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 17, 2009
Comparative toxicity of preservatives on immortalized corneal and conjunctival epithelial cellsSeth P Epstein, Michael Ahdoot, Edward Marcus, et al.
Frontiers in Oncology|April 17, 2023
Identifying novel biomarkers associated with bladder cancer treatment outcomesPeris R Castaneda, Dan Theodorescu, Charles J Rosser, et al.
Prostate Cancer and Prostatic Diseases|March 5, 2022
Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomesJohn R Heard, Aurash Naser-Tavakolian, Michael Nazmifar, et al.
Pageof 5